Chester County News and Community Website
WILMINGTON, DE — AstraZeneca has announced groundbreaking results from the BATURA Phase IIIb trial for AIRSUPRA (albuterol/budesonide), marking a significant advancement in asthma care. The anti-inflammatory rescue therapy demonstrated substantial …
AstraZeneca’s BATURA Trial Highlights Breakthrough Results for Asthma Treatment Read More WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance …
AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBC Read More WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) …
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer Read More WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise for its fixed-dose triple-combination therapy, BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or …
AstraZeneca Reports Promising Phase III Trial Results for BREZTRI AEROSPHERE Read More WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly statistically significant and clinically meaningful improvement in …
DESTINY-Breast09 Trial Demonstrates Promising Results for ENHERTU in Combination with Pertuzumab Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More WILMINGTON, DE — New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers significant reductions in LDL cholesterol (LDL-C) when combined with standard-of-care statin …
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial Read More WILMINGTON, DE — AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer (MIBC), making it the first perioperative immunotherapy available in the U.S. …
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer Read More WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. The trial demonstrated …
AstraZeneca’s AIRSUPRA Proven Effective in Reducing Severe Asthma Attacks Read More